PSMA PET/MRI for Predicting and Detecting Prostate Cancer
NCT07924605, Phase 2, Not yet recruiting, University of Wisconsin, Madison
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | PSMA PET/MRI for Predicting and Detecting Prostate Cancer | ClinicalTrials.gov |
| NCT number | NCT07924605 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Wisconsin, Madison | ClinicalTrials.gov |
| Conditions | Prostate Cancer, High-Risk Localized Prostate Cancer, Locally Advanced Prostate Cancer, Low-Risk Prostate Cancer, Intermediate Risk Prostate Cancer | ClinicalTrials.gov |
| Interventions | PSMA PET, MRI, 18F-DCFPyL | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Pathologic tumor volume (Study 1 only) | 75 minutes | Imaging response between baseline and pre-prostatectomy PSMA PET/MRI will be measured to learn if it can predict final pathologic tumor volume. Evaluating whether changes in PSMA PET and MRI using quantitative imaging variables (SUV, tumor volume PSMA, ADC, DWI) from baseline to pre-prostatectomy imaging predict final pathologic tumor volume on whole-mount radical prostatectomy using 3D mold. | ClinicalTrials.gov |
| Primary | The ability of PSMA PET to improve detection of clinically significant cancer (Study 2) | 75 minutes | The rate of positive cancer detection using PET/MRI directed MRI/transrectal ultrasound (TRUS) fusion biopsy with and without additional PSMA PET information | ClinicalTrials.gov |
| Secondary | Final pathologic tumor volume (Study 1) | 75 minutes | Compare the ability of pre-prostatectomy PSMA PET/MRI versus mpMRI alone to predict final pathologic tumor volume. | ClinicalTrials.gov |
| Secondary | Diagnostic accuracy (Study 2) | 75 minutes | True positive, false positive rate of PSMA PET alone versus mpMRI alone versus combined PSMA PET with mpMRI on a lesion-based and patient-based analysis in patient with very low to intermediate risk prostate cancer | ClinicalTrials.gov |
| Secondary | Rate of management change based on biopsy results (Study 2) | Baseline, 18 months | The rate of management change based on mpMRI-directed biopsy results alone versus mpMRI- and PSMA PET-directed biopsy results | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)